Kezar Life Sciences, Inc. - Common Stock, $0.001 par value (KZR) Institutional Ownership

CUSIP: 49372L100

13F Institutional Holders and Ownership History from Q2 2018 to Q1 2025

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
KZR on Nasdaq
Shares outstanding
7,354,969
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Investment Quick Answers

What is CUSIP 49372L100?
CUSIP 49372L100 identifies KZR - Kezar Life Sciences, Inc. - Common Stock, $0.001 par value in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Significant Owners of Kezar Life Sciences, Inc. - Common Stock, $0.001 par value (KZR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BML Investment Partners, L.P. 9.8% +94% 720,787 +96% BML Investment Partners, L.P. 31 Dec 2025
Equal Talent Investments Ltd 8.7% $487,037 616,502 Equal Talent Investments Limited 28 Feb 2025
Avidity Partners Management LP 6.9% $397,054 502,600 Avidity Partners Management LP 31 Dec 2024

Institutional Holders of Kezar Life Sciences, Inc. - Common Stock, $0.001 par value (KZR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q1 0 $0 -$2,838 0
2024 Q4 0 $0 -$28,947,595 0
2024 Q3 37,449,865 $28,947,595 +$900,937 $0.77 54
2024 Q2 39,365,394 $23,615,883 -$3,995,490 $0.60 77
2024 Q1 44,720,608 $40,307,361 -$4,363,680 $0.90 80
2023 Q4 49,383,993 $46,782,011 -$6,015,885 $0.95 81
2023 Q3 55,483,503 $66,015,535 -$3,021,557 $1.19 81
2023 Q2 56,853,940 $139,289,225 -$10,696,353 $2.45 102
2023 Q1 60,086,283 $188,069,347 -$2,895,034 $3.13 135
2022 Q4 57,438,478 $404,373,495 -$10,789,742 $7.04 123
2022 Q3 57,567,548 $495,653,323 +$24,341,050 $8.61 131
2022 Q2 54,911,473 $454,020,310 +$61,154,299 $8.27 125
2022 Q1 44,191,085 $734,149,889 +$63,780,372 $16.62 121
2021 Q4 39,383,430 $658,088,801 +$203,357,999 $16.72 103
2021 Q3 28,072,081 $242,729,438 +$7,811,950 $8.64 75
2021 Q2 27,643,703 $150,101,213 +$4,146,701 $5.43 73
2021 Q1 26,470,809 $157,211,005 +$18,317,371 $5.96 79
2020 Q4 23,537,490 $122,866,361 +$1,908,188 $5.22 75
2020 Q3 23,177,080 $112,175,583 -$609,875 $4.84 75
2020 Q2 23,193,481 $119,558,636 +$25,836,495 $5.18 82
2020 Q1 18,491,349 $80,617,885 +$40,696,616 $4.36 58
2019 Q4 9,173,287 $36,785,829 -$692,653 $4.01 54
2019 Q3 9,424,823 $30,911,164 -$5,442,310 $3.28 53
2019 Q2 10,011,636 $77,168,911 +$5,806,241 $7.71 53
2019 Q1 9,915,066 $175,891,040 +$12,160,103 $17.74 50
2018 Q4 9,337,563 $220,365,047 +$7,169,032 $23.60 40
2018 Q3 9,054,013 $193,850,000 +$20,016,802 $21.41 37
2018 Q2 8,162,306 $141,208,000 +$141,208,000 $17.30 27